Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company in Shanghai. The collaboration aims to promote Lonasen (blonanserin) and Latuda (lurasidone), both antipsychotic medications, in the Chinese market. Financial details of the partnership were not disclosed.
Epidemiological Context
According to the latest epidemiological survey in China, the 12-month prevalence rate of schizophrenia is 0.6%, equating to approximately 8 million individuals with schizophrenia in the country. This represents a significant burden on individuals, families, healthcare infrastructure, and society. The partnership between Sumitomo Dainippon and Profex is expected to enhance access to effective treatments for schizophrenia.
Market Presence and Approvals
Sumitomo Dainippon launched its antidepressant Sediel (tandospirone) in China in 2003. The company obtained marketing approvals for Lonasen and Latuda in 2018 and 2019, respectively. Both drugs were included in China’s National Reimbursement Drug List (NRDL) in 2020, further solidifying their market presence in the country.-Fineline Info & Tech
